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Abstract
Background: Several studies have shown that mammographic texture features are associated with breast cancer
risk independent of the contribution of breast density. Thus, texture features may provide novel information for risk
stratification. We examined the association of a set of established texture features with breast cancer risk by tumor
type and estrogen receptor (ER) status, accounting for breast density.
Methods: This study combines five case–control studies including 1171 breast cancer cases and 1659 controls
matched for age, date of mammogram, and study. Mammographic breast density and 46 breast texture features,
including first- and second-order features, Fourier transform, and fractal dimension analysis, were evaluated from
digitized film-screen mammograms. Logistic regression models evaluated each normalized feature with breast
cancer after adjustment for age, body mass index, first-degree family history, percent density, and study.
Results: Of the mammographic features analyzed, fractal dimension and second-order statistics features were
significantly associated (p < 0.05) with breast cancer. Fractal dimensions for the thresholds equal to 10% and 15%
(FD_TH_10 and FD_TH_15) were associated with an increased risk of breast cancer while thresholds from 60% to
85% (FD_TH_60 to FD_TH_85) were associated with a decreased risk. Increasing the FD_TH_75 and Energy feature
values were associated with a decreased risk of breast cancer while increasing Entropy was associated with a
increased risk of breast cancer. For example, 1 standard deviation increase of FD_TH_75 was associated with a 13%
reduced risk of breast cancer (odds ratio = 0.87, 95% confidence interval 0.79–0.95). Overall, the direction of
associations between features and ductal carcinoma in situ (DCIS) and invasive cancer, and estrogen receptor
positive and negative cancer were similar.
Conclusion: Mammographic features derived from film-screen mammograms are associated with breast cancer risk
independent of percent mammographic density. Some texture features also demonstrated associations for specific
tumor types. For future work, we plan to assess risk prediction combining mammographic density and features
assessed on digital images.
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Background
Women with mammographically dense breasts are at a
higher risk of developing breast cancer than women with
more fatty breasts. The risk of developing breast cancer
can be four- to six-times higher in women with breast
density in the top quartile of the population compared
to the bottom quartile [1, 2]. Why breast density is pre-
dictive of future cancer occurrence is not fully known.
What is known is that breast density is not homoge-
neous. Some of the earliest measures of breast density
categorized the appearance of mammograms by the pat-
terns projected from the heterogeneity of the tissue [3].
However, the description of the heterogeneity, or “texture”,
has not been incorporated in standardization reporting of
breast density categories in the Breast Imaging-Reporting
and Data System (BI-RADS) [4], or the quantitative
measures of volumetric breast density using methods such
as the Volpara (Matakina, Wellington, New Zealand) and
Quantra (Hologic, Inc., Marlborough, MA, USA) [5].
Breast density texture can be described using numerous
statistical descriptors of the distribution and spatial rela-
tionship of grayscale values in the image pixels. Texture has
been studied as a breast cancer risk factor independent of
average breast density [6–11], but the results have not been
adequately adjusted for breast density and other risk
factors. For example, Byng et al. reported a negative sig-
nificant correlation between regional skewness, fractal
dimension, and cancer risk [7]. However, Torres-Mejia
et al. [6] reported that the regional skewness and fractal
dimensions had no association with breast cancer after
adjusting for other risk factors and overall breast density.
One feature, lacunarity, remained significant [6]. Manduca
et al. found that skewness and kurtosis did not predict
breast cancer risk [8], but did find associations for the
Markovian, run length, Laws, wavelet, and Fourier trans-
formations. After adjustment for planar mammographic
percent density (PD), each feature attenuated only slightly
and retained statistical significance; however, simultaneous
inclusion of these features in a model with PD did not sig-
nificantly improve the ability to predict breast cancer [8].
Other studies have shown that differences in texture and
density features are related to predisposing mutations and
tumor type including BRCA1/BRCA2 mutation carriers
[12–14] and estrogen receptor (ER) status [15–17]. Thus,
the density patterns of the parenchymal tissue have
attracted clinical attention because of their potential to
offer additional information about subtype and cancer
biology. However, it remains unknown if breast texture
descriptors will help better identify women at high risk of
breast cancer from standard screening mammograms.
To this end, we amassed a library of imaging features
previously reported on in the breast imaging and general
imaging literature as candidate descriptors of breast tissue
characteristics. In this study, we investigated the association
of these descriptors and breast cancer risk using prospect-
ively acquired mammograms from five breast cancer epi-
demiology studies. We also examined the association of
these descriptors to tumor type and ER status.
Methods
Study design
This study is a large, comprehensive pooled analysis of
five case–control studies, two of which were nested
within cohorts, to examine the association between texture
of mammographic density and breast cancer risk and breast
cancer subtypes.
Study population
The studies and populations used in this analysis have
been previously described elsewhere [16]. Briefly, the
participating studies included the Mayo Mammography
Health Study (MMHS) [18], the Nurses’ Health Studies
(NHS and NHSII) [19], the Mayo Clinic Mammography
Study (MCMAM) [20], and the San Francisco Bay Area
Breast Cancer SPORE and San Francisco Mammography
Registry (SFMR) at the University of California San
Francisco (UCSF) [21]. Breast cancer cases diagnosed
within 6 months of mammography were excluded from
all studies. We collected covariate data from medical
record review (MCMAM), and self-administered ques-
tionnaires (NHS, NHSII, SFMR), or both (MMHS). In-
formation was obtained before (NHS, NHSII) or at the
time of (MMHS, MCMAM, SFMR) screening mammo-
gram. The Institutional Review Boards at the Mayo
Clinic, Brigham and Women’s Hospital, UCSF, and the
Connecticut Department of Public Health Human
Investigations Committee reviewed and approved these
studies. Informed consent was obtained or implied by
return of questionnaires (NHS, NHSII).
There were 9353 women with screening visits during
the study period from all studies. For MMHS and
SFMR only, due to study design, large batches of cases
were digitized at one time followed later by batches of
matched controls. Thus, to ensure no bias due to po-
tential confounding by digitization we only included
those cases and matched controls that were digitized
in the same batches, resulting in a substantially re-
duced sample for these two studies. To ensure that no
bias was associated with study exclusions due to
digitizer in these two studies, we compared the in-
cluded cancer cases to the excluded cancer cases. We
found that the eligible vs. excluded cases did not differ
in terms of their demographic and clinical characteris-
tics (P > 0.05). Similarly, matched controls were com-
pared against the whole study population and were
found to be comparable (data not shown). Overall,
2830 women were eligible for our case–control set and
6523 (69.7% of population) from MMHS and SFMR
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were excluded. Of these, mammograms of 1171 breast
cancer cases and 1659 controls were analyzed.
Mammogram digitization and harmonization
For this study, the craniocaudal (cc) views of screening
examinations of both breasts were digitized at each
respective study site. The cc view images were more
conducive to being analyzed automatically with our algo-
rithms; also, not all studies had mediolateral oblique
views available. The MMHS screen-film mammograms
were digitized on the Array 2905 laser digitizer (Array
Corporation, The Netherlands) that has 50-μm (limit-
ing) pixel spacing with 12-bit grayscale bit depth. The
MCMAM mammograms were digitized on a Lumiscan
85 scanner with 12-bit grayscale bit depth and 0.100 ×
0.100 mm2 pixel size. For mammograms provided by
the SFMR, digitization was performed using two digi-
tizers, a R2 ImageChecker with 16-bit dynamic range
and 150-μm pixel size, and a Vidar Diagnostic Pro
(Vidar Systems Corporation) with 16-bit dynamic range
and 169-μm pixel size. For NHS and NHSII, film mam-
mograms were digitized at 261 μm per pixel with a
Lumisys 85 laser film scanner (Lumisys, Sunnyvale, CA,
USA) or a VIDAR CAD PRO Advantage scanner
(VIDAR Systems Corporation, Herndon, VA, USA) and
comparable resolution of 150 dots per inch and 12 bit
depth. To minimize effects of the film digitization
process, we performed a harmonization procedure by
rescaling all images to have the same pixel size and
dynamic range. The ultimate space resolution was set
to 160 μm using a Matlab “imresize” function with de-
fault parameters (bicubic interpolation). The dynamic
scale of all images was converted into 16-bit grayscale
by the proper coefficient multiplication.
Assessment of mammographic density
To quantify PD, two semi-automatic threshold techniques
were applied: Cumulus [22] (all studies besides SFMR) and
UCSF custom software [23] (SFMR study; comparable to
Cumulus). The test at the beginning of the study demon-
strated that there was high correlation between the UCSF
and Cumulus methods. As documented in [16], similar
results are obtained from an average of both breasts
and from a randomly selected side. We quantified PD on
the contralateral breast for cases and the corresponding
side for matched controls for all studies except NHS and
NHSII where the average PD of both left and right views
were used. Only one reader read the images at each site.
To match PD measures between readers and studies, we
standardized the readings by removing the study-specific
age trends, standardizing the variability across studies, and
incorporating the known age trend in PD into the stan-
dardized PD. Details of this standardization procedure
have been previously published [16].
Breast texture measurements
We automated 46 candidate image texture features into
our mammography image analysis program (Table 1).
Features were measured on both left and right cc views
for all subjects. The texture analysis was performed in
the entire breast area. The entire breast area was auto-
matically segmented from the background by global
thresholding. Texture measures were grouped by the
type of statistical description. Features derived from the
histogram of the mammographic grayscale values were
grouped as “Gray-Level Histogram” and include the
image Standard Deviation, Skewness, Kurtosis, and Balance
[7, 22, 24–26]. The second-order features described the
spatial relationships between pixel intensities. We derived
these second-order features using two matrixes: gray-level
co-occurrence matrix (GLCM) [24, 25, 27] and neighbor-
hood gray-tone difference matrix (NGTDM) [24, 28]. The
GLCM matrix defined the distribution of co-occurring
values at a given pixel offset in the image. Because co-
occurrence matrices were often large and sparse, various
metrics were used to describe the features of the matrix.
The GLCM matrix was created by Matlab “graycomatrix”
function with a number of gray levels equal to 16 and off-
set = [0 1] related to horizontal proximity of the pixels. The
features used to describe a GLCM are often called Haralick
features [27], and include Energy, Entropy, Dissimilarity,
Contrast, Homogeneity, Correlation, Mean and Variance. In
the textural analysis, the GLCM Entropy represents image
pixel spatial disorder (e.g., heavy heterogeneous textures
versus a flat gray level and smooth textures). The GLCM
Energy represents local homogeneity and is a measure
opposite to GLCM Entropy. Actually, this texture feature
describes the degree of texture uniformity; basically, more
homogeneous texture has a higher Energy. For example,
the image with only constant grayscale pixels has Energy
equal to 1. Other similar texture features from this table are
GLCM Homogeneity and Dissimilarity. Homogeneity mea-
sures how uniform are the non-zero entries in the GLCM
matrix. This feature represents existence of repetitions in
texture. The image with irregular texture elements and
their spatial positions is characterized by low Homogeneity.
An image that contains repetitive structures represents high
Homogeneity. Dissimilarity is a measure that defines the
variation of gray level pairs in an image. It is very similar to
Contrast with a difference in the weight.
The NGTDM is a column matrix, which was first
defined by Amadasun and King [28]. This matrix was
derived by calculating the gray level difference between
pixels with a certain gray level and their neighboring
pixels. The NGTDM features included were Coarseness,
Contrast, Complexity, Strength and Busyness [24, 28].
One feature, the mean gradient, was from a group of
features called the Edge Frequency Analysis group.
Lastly, Fourier and fractal analysis groups defined the
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remainder of the features. Fourier transform (FT) opera-
tions were used to estimate features in the frequency do-
main: root mean square (FT_RMS), first (FT_FMP) and
second (FT_SMP) moments of power spectrum, and
fractal dimension (FD) from power spectrum exponent
(FT_FD) [29]. To define fractal qualities, shapes within
the image were created using the pixels at a percentage
threshold value of the total contrast (i.e., FD_TH_X, for
threshold at X = 5, 10, 15…85%). These features were de-
rived by a box counting method. Further fractal features
include FD of the standard deviation (FD_Sigma), inter-
cept of the plot of the standard deviation of the high fre-
quency image as a function of the size the kernel
(CD_Yint), slope of the plot of the standard deviation of
the high-frequency image as a function of the size the
kernel (CD_Slope), standard deviation of the mean value
of the breast pixels rows (HZ_PROJ), FD of the surface
of the breast considering the gray value represents the
height (FD_CALDWELL) [30, 31], and Minkowski fractal
dimension (FD_Minkowski) derived from morphological
image operations [29]. The FD_Minkowski is similar to
the box counting fractal dimensions (i.e., FD_TH vari-
ables). It is calculated by an image dilation procedure
with different scale structure disk element. As a result of
edge frequency analysis, the mean gradient parameter
was created. We previously demonstrated the utility of
this set of features for derivation of volumetric breast
density by a statistical model approach [32].
Table 1 Image texture features that are currently defined for all study participants
Analysis groups Texture features Texture feature name References










GLCM Mean GLCM Mean
GLCM Variance GLCM Variance
Neighborhood gray-tone difference
matrix (NGTDM)
NGTDM Coarseness NGTDM Coarseness [24, 28, 29]




Edge frequency analysis Mean gradient Mean_Gradient [29]
Fourier transform (FT) analysis,
power spectrum
RMS (root mean square) FT_RMS [29]
FMP (first moment of power spectrum) FT_FMP
SMP (second moment of power spectrum) FT_SMP
FD (fractal dimension) from power spectrum exponent FT_FD
Fractal analysis Intercept of the plot of the standard deviation of the
high frequency image as a function of the size the kernel
CD_Yint [29–31]
Continuous dimension (CD), slope and intercept CD_Slope
HZ_PROJ HZ_PROJ
FD of the standard deviation FD_Sigma
FD of image using thresholds from 5%-85% FD_TH_5: FD_TH_85
FD of the surface of the breast considering the gray value
representing the height
FD_CALDWELL
FD, Minkowski method FD_Minkowski
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Assessment of tumor characteristics
Tumor type (invasive vs. ductal carcinoma in situ (DCIS))
and ER status were available using Northern and Southern
California Surveillance Epidemiology and End Results
programs for SFMR, pathology reports or immunohis-
tochemical analysis of tumor microarrays for NHS and
NHSII, and state and clinic cancer registries for MMHS
and MCMAM.
Statistical analysis
Risk factors and PD phenotypes were harmonized on the
eligible cases and controls. For all subjects, concordance
between features measured on left and right sides were
evaluated. Lin’s concordance correlation coefficients were
used to summarize the correlation between left and right
sides. Values ranged from 0.50 to 0.98 with median of
0.85. Given this, we chose to average sides to reduce noise
in the measurements. To avoid issues with outliers and
violations of distributional assumptions, the averaged fea-
tures were normalized within each study using a normal
transformation of the ranks. All analyses were performed
using the normalized features. Logistic regression models
evaluated the overall breast cancer associations with each
normalized feature as a continuous variable and results
are presented as odds ratio (OR) per 1 standard deviation
(SD). All models were adjusted for age (continuous), body
mass index (BMI) (continuous), first-degree family history
of breast cancer (yes vs. no vs. unknown), PD (continu-
ous), and study. To assess whether there were differences
in associations by study, we included and tested an inter-
action term for texture feature by study. Study-specific
results were also examined and summarized. The top 15
of 46 analyzed features that were significant (p < 0.05) in
the case–control models were selected for further analysis.
Polytomous logistic regression models were fitted to
examine associations of features with respect to invasive/
DCIS breast cancers and ER status. Contrasts were con-
structed within the polytomous model framework to test
for differences of feature associations between tumor sub-
groups (p-het). SAS version 9.3 was used for analyses and
two-sided p values < 0.05 were considered to be statisti-
cally significant. Pearson correlation coefficients were used
to examine correlations among features and also corre-
lations of features with PD among control subjects.
Dendrograms were created to illustrate clustering among
the significant features, age, body mass index (BMI), and
PD on data from controls. A hierarchical clustering
method using averaged distance was utilized as imple-
mented in “proc cluster” in SAS.
Results
The baseline case and control characteristics of the eligible
population are shown in Table 2. The cases had stronger
family history and were more likely to have higher PD
compared with controls. Both cases and control groups
were of similar age, BMI, menopause status, and parity.
The baseline characteristics of the study population
separated by study site are presented in Additional file 1
(Table S1). The NHSII site population is different from
other sites by lower age, premenopausal prevalence, and
higher PD. The baseline characteristics of study popula-
tion separated by study site demonstrate similar trends
between cancers and controls as above mentioned.
The top 15 of 46 analyzed features had a statistically
significant (p < 0.05) association with breast cancer
Table 2 Baseline characteristics of study population matched
by age, date of mammogram, and study
Cases Controls
N 1171 1659
Mean age at mammogram (years) 55.4 (10.6) 55.3 (10.6)
Mean age at diagnosis (years) 60.5 (10.8) –
Mean BMI (kg/m2) 25.7 (6.1) 25.8 (6.8)
Body mass index categories (kg/m2)*
< 25 551 (47.1%) 854 (51.5%)
25–29 369 (31.5%) 443 (26.7%)
30–34 155 (13.2%) 196 (11.8%)
35+ 73 (6.2%) 136 (8.2%)
Unknown 23 (2.0%) 30 (1.8%)
Menopausal Status
Premenopausal 430 (36.7%) 632 (38.1%)
Postmenopausal 697 (59.5%) 962 (58%)
Unknown 44 (3.8%) 65 (3.9%)
Parity
Nulliparous 169 (14.4%) 218 (13.1%)
Parous 977 (83.4%) 1415 (85.3%)
Unknown 25 (2.1%) 26 (1.6%)
Postmenopausal hormone therapya*
Not current 255 (51.5%) 367 (57.5%)
Current, estrogen 116 (23.4%) 156 (24.5%)
Current, estrogen + progestin 124 (25.1%) 115 (18.0%)
Family history*
No 973 (83.1%) 1453 (87.6%)
Yes 196 (16.7%) 206 (12.4%)
Unknown 2 (0.2%) 0 (0%)
Standardized mean percent mammographic
density (%)*
32.9 (18.7) 27.9 (18.4)
Standardized mean dense area (cm2)* 63.5 (43.1) 52.2 (37.8)
Standardized mean non-dense area (cm2)* 149.4 (98.7) 158.9 (102.1)
Data are presented as the mean (standard deviation) or number (%).
aAmong postmenopausal women in MMHS, NHS, NHSII, and SFMR
*p < 0.05, cases versus controls
BMI body mass index
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after adjustment for age, BMI, family history, PD, and
study (Table 3). It should be noted that the features
mostly follow the same trend across studies even
though some are not significant in their separate OR
estimation, and there was no evidence of study hetero-
geneity for any feature (p > 0.05 for all). Study-specific
estimates for SFMR were often not consistent with
other studies. In sensitivity analysis, we excluded SFMR to
explore the impact of these differences and found similar
results (data not shown). Three features with the strongest
association were FD_TH_75, Energy, and Entropy. Increas-
ing the FD_TH_75 and Energy feature values were associ-
ated with a decreased risk of breast cancer while increasing
Entropy was associated with an increased risk of breast
cancer. The fractal dimension features were separated
into two groups. The first group described the fractal
dimensions in the densest pixels, and contained fea-
tures FD_TH_60, FD_TH_65, FD_TH_70, FD_TH_75,
FD_TH_80, FD_TH_85, and FD_Minkowski. All these
features were significant and were associated with a de-
crease in cancer risk with the most significant associ-
ation OR (95% confidence interval (CI)) per 1 SD = 0.87
(0.79–0.95) for FD_TH_75. The second feature group
described fractal dimensions in the lower density (less
opaque) pixels: FD_TH_10 and FD_TH_15. In contrast
to the first group, they were associated with an increase
in breast cancer risk. Energy and Entropy demonstrate
opposite associations to cancer with OR (95% CI) 0.88
(0.81–0.96) and 1.14 (1.05–1.25), respectively. The
GLCM features Homogeneity and Dissimilarity showed
opposite trends with OR (95% CI) 1.10 (1.01–1.20) and
0.91 (0.83–0.99), respectively. Table 3 also demon-
strates the results of area under the curve (AUC) ana-
lysis of different feature models. For the baseline model
(adjusted for age, BMI, family history, PD, and study),
AUC was 0.617 and with with top feature (FD_TH_75)
it was 0.621, suggesting modest increases in discrimin-
ation with the addition of this texture feature.
Figure 1 shows the dendrogram noting the clustering of
the top 15 features and clinical risk factors (PD, age, BMI)
restricted to the control subjects (see Additional file 2:
Figure S1 for clustering results restricted to the cases). The
features separated into two primary clusters. Within the
first cluster, features FD_TH_60 through FD_TH_85
formed a subcluster separate from the other non-feature
risk factors. Interestingly, the clinical risk factors (BMI, age,
PD) form a subcluster with Kurtosis and Busyness inde-
pendent of other features. The second main cluster includes
pairs of Entropy/Energy, Dissimilarity/Homogeneity, and
FD_TH_10/FD_TH_15. The intercorrelation of each feature
and risk factor calculated using control subjects is shown in
Table 4 (see Additional file 1: Table S2 for intercorrelation
calculated using case subjects). Interestingly PD is highly
correlated to features similar to FD_TH_75, FD_Minkowski
Table 3 The top 15 of 46 analyzed features were significant (p < 0.05) in the case–control models
Feature All five studies OR
(95% CI)










N case/N control 1171/1659 62/112 242/395 104/206 412/454 351/492
FD_TH_75 0.87 (0.79–0.95) 0.003 0.621 0.76 (0.48–1.20) 0.73 (0.56–0.94)* 1.28 (0.90–1.82) 0.94 (0.80–1.11) 0.84 (0.72–0.98)*
Energy 0.88 (0.81–0.96) 0.003 0.621 1.03 (0.71–1.51) 0.84 (0.70–1.01) 1.35 (0.97–1.89) 0.85 (0.73–0.98)* 0.86 (0.73–1.00)
Entropy 1.14 (1.05–1.25) 0.003 0.620 1.01 (0.68–1.51) 1.30 (1.06–1.59)* 0.75 (0.54–1.04) 1.19 (1.02–1.38)* 1.13 (0.96–1.32)
FD_TH_70 0.87 (0.79–0.96) 0.005 0.621 0.88 (0.55–1.43) 0.72 (0.55–0.94)* 1.28 (0.87–1.87) 0.97 (0.82–1.15) 0.82 (0.70–0.96)*
FD_TH_80 0.89 (0.82–0.98) 0.012 0.620 0.86 (0.56–1.31) 0.88 (0.70–1.12) 1.17 (0.84–1.64) 0.90 (0.77–1.06) 0.87 (0.75–1.01)
FD_TH_10 1.11 (1.02–1.20) 0.015 0.620 1.43 (1.00–2.06) 1.11 (0.92–1.34) 1.07 (0.80–1.42) 1.03 (0.89–1.19) 1.15 (0.98–1.34)
Kurtosis 0.89 (0.81–0.98) 0.015 0.620 0.91 (0.61–1.34) 0.85 (0.69–1.06) 0.84 (0.60–1.16) 0.86 (0.74–1.01) 0.95 (0.80–1.12)
FD_TH_65 0.88 (0.80–0.98) 0.016 0.620 0.95 (0.57–1.58) 0.78 (0.59–1.04) 1.50 (0.98–2.29) 0.97 (0.82–1.15) 0.81 (0.68–0.96)*
FD_Minkowski 0.88 (0.79–0.98) 0.017 0.621 0.65 (0.34–1.24) 0.85 (0.67–1.09) 1.07 (0.72–1.59) 0.84 (0.70–1.00)* 0.91 (0.74–1.13)
Busyness 1.10 (1.02–1.20) 0.019 0.619 1.43 (0.97–2.13) 1.17 (0.97–1.41) 1.00 (0.74–1.35) 0.99 (0.86–1.15) 1.18 (1.02–1.38)*
Homogeneity 1.10 (1.01–1.20) 0.023 0.620 1.43 (0.95–2.14) 0.92 (0.76–1.13) 1.38 (1.00–1.90) 1.09 (0.94–1.26) 1.18 (1.01–1.37)*
Dissimilarity 0.91 (0.83–0.99) 0.033 0.620 0.72 (0.48–1.09) 1.10 (0.90–1.34) 0.74 (0.53–1.03) 0.92 (0.79–1.06) 0.85 (0.73–0.99)*
FD_TH_60 0.89 (0.80–0.99) 0.035 0.620 1.02 (0.60–1.73) 0.74 (0.55–0.98)* 1.49 (0.95–2.33) 1.00 (0.83–1.19) 0.82 (0.68–0.98)*
FD_TH_85 0.92 (0.84–1.00) 0.046 0.619 0.98 (0.65–1.46) 0.89 (0.71–1.11) 1.12 (0.82–1.53) 0.93 (0.79–1.08) 0.90 (0.78–1.05)
FD_TH_15 1.09 (1.00–1.18) 0.048 0.619 1.42 (0.96–2.11) 1.09 (0.91–1.31) 1.04 (0.79–1.39) 0.96 (0.83–1.11) 1.21 (1.04–1.42)*
Features listed in italics were significant in at least two studies.
Results are presented as odds ratio (OR) and 95% confidence interval (CI) per 1 standard deviation in normalized feature after adjustment for age, body mass
index (BMI), family history, percent density (PD), and study.
aAdjusted for age, BMI, family history, PD, and study. Area under the curve (AUC) for the adjustment factors only is 0.617 (95% CI 0.596–0.638)
*Study p values < 0.05.
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and Kurtosis from the same primary cluster group. How-
ever, the features of the second primary cluster show no or
negligible association with PD.
Figure 2 shows representative images with similar
densities but different feature values for the FD_TH_75
feature. We selected images with FD_TH_75 values in
the top and bottom 20% of values matched by BMI, PD,
age, case status, and study. The top row of Fig. 2 has
similar low PD densities (17%) while the bottom row has
a relatively high PD (67%). The inner black delineation
lines in each breast image show the delineation lines of
the tissue used to describe FD_TH_75. The outer black
delineation lines show the delineation lines of the tissue
used to describe FD_TH_15. The top left and bottom
1.0 0.9 0.8 0.7 0.6 0.5 0.4




















Fig. 1 Dendrogram of cluster analysis of the top 15 features with PD, age, and BMI. Similar features cluster together. Percent density groups
closely with body mass index (BMI) and age. The figure is restricted to the controls
Table 4 Pearson correlation coefficient for the top 15 significant features
Correlations calculated using control subjects. Gray and gray with line patterns highlight the strength of positive and negative associations, respectively
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left images show a top 20th percent tile value of
FD_TH_75 while the top right and bottom right images
show a bottom 20th percent tile value.
In Table 5, the breast cancer risk associated with DCIS
and invasive cancer is shown for the 15 most significant
features found overall, adjusted for age, BMI, and PD.
While invasive cancers have approximately the same
significant features as the all-cancer results in Table 2,
DCIS showed a smaller number of significant associations
with features. FD_TH_10 and FD_TH_15 significantly as-
sociated with DCIS risk, but not with invasive cancer. Five
features were significantly associated with the ER+ cases
(Table 5) while no features were significantly associated
with ER– status, although power was limited. The patterns
of association were similar for risk of DCIS, invasive
breast cancer, and ER+ and ER– breast cancer.
Discussion
The combined results of five separate studies, including
1171 cancer cases and 1659 controls, were used to study
the association of mammographic textural features on
film-screen mammograms, independent of PD, with breast
cancer risk overall and defined by tumor type and ER
status. Of the 46 features studied, several candidate features
demonstrated an association with breast cancer overall.
The addition of individual texture features to the baseline
model (adjusted for age, BMI, family, PD, and study)
demonstrated modest increases in the discriminatory
ability of the model. The patterns of association were
found to be similar for the risk of DCIS, invasive breast
cancer, and ER+ and ER– breast cancer, although there
were differences in magnitude of the associations between
invasive/DCIS, ER+/ER– status cancer subtypes, and
Fig. 2 Representative images with similar densities but different groups: FD_TH_75 values in the top and bottom 20% of values matched by BMI,
PD, age, case status, and study. The top row has similar low PD densities (17%) while the bottom row has a relatively high PD (67%). The inner
black delineation lines in each breast image show the delineation lines of the tissue used to describe FD_TH_75. The outer black delineation lines
show the delineation lines of the tissue used to describe FD_TH_15. The top left and bottom left images show a top 20th percent tile value of
FD_TH_75 while the top right and bottom right images show a bottom 20th percent tile value
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specific features. We also found that many mammo-
graphic features associated with breast cancer were not
correlated with PD, a desirable quality for potentially im-
proving the discrimination of risk-prediction models. Spe-
cifically, the GLCM Entropy/Energy and Homogeneity/
Dissimilarity, Busyness, FD_15, and FD_10 features may
be tested in combination with PD in risk-prediction
models.
In previous reports, there have been few examples of
texture features that are associated with cancer independ-
ent of PD. Torres-Mejia et al. [6] found no significant
breast cancer risk association of fractal features after
adjusting for PD, and Manduca et al. [8] found that fea-
tures did not add additional significance when adjusted
for PD. We found several fractal dimension features asso-
ciated with breast cancer risk (FD_TH_5:FD_TH_85), but
the association was reversed dependent on the threshold
level used to create the line profiles. An example was
given of the FD_TH_75 (line profile outlining highly dense
tissue) and FD_TH_15 (line profile outlining the edge of
the compressed area) in Fig. 1. Thus, the reversal in asso-
ciation from high to low risk is associated with defining
fractal characteristics in different types of tissue. Another
fractal dimension feature, FD_Minkowski, showed a de-
creased association with cancer risk similar to FD_TH_75.
These measures are closely mathematically related as
noted by their clustering in the dendrogram. Unlike other
studies, the association of FD_Minkowski feature with
breast cancer risk [6] remained significant after adjust-
ment for PD and other risk factors.
Other associated features include the paired features
Entropy and Energy as well as Homogeneity and Dis-
similarity. The Entropy is intuitively assumed to be
significant for breast cancer risk because tissue with
high entropy is more heterogeneous. Energy value is
associated with a reduced risk of breast cancer because it
is related to tissue with more homogeneous texture. The
features that denoted more coarseness increased risk and
those that were less coarse did not increase risk or were
protective. The Pearson correlation coefficients show the
features in both pairs are highly negatively correlated. The
protective character of Dissimilarity (or Contrast) is not
intuitive. We can speculate that finer structure has high
contrast and has similar behavior to fractal dimension.
Other studies provided an important role for mammo-
graphic textures such as fractal dimensions, GLCM matrix
parameters, and power Fourier spectrum in distinguishing
between BRCA1/BRCA2 gene mutations and cancer risks
[29, 33]. These results are consistent with the results of
our study. The fractal dimension and GLCM features
derived in our study also demonstrate a significant associ-
ation with breast cancer risk. The cause and underlying
biology of mammographic feature association to breast
cancer risk is complex. The features responsible for
Table 5 Risk associated of either DCIS or invasive cancer for each feature
Feature DCIS Invasive ER– ER+
OR (95% CI) OR (95% CI) p value* p het** OR (95% CI) OR (95% CI) p value* p het**
N case/N control 254/1659 908/1659 116/1291 746/1291
FD_TH_75 0.87 (0.74–1.01) 0.87 (0.78–0.96) 0.010 0.98 0.84 (0.67–1.06) 0.88 (0.79–0.99) 0.048 0.72
Energy 0.88 (0.76–1.02) 0.88 (0.80–0.96) 0.011 0.93 0.85 (0.69–1.05) 0.86 (0.78–0.95) 0.009 0.90
Entropy 1.18 (1.02–1.38) 1.13 (1.03–1.25) 0.010 0.60 1.16 (0.93–1.44) 1.15 (1.03–1.28) 0.024 0.96
FD_TH_70 0.85 (0.72–1.00) 0.87 (0.79–0.97) 0.015 0.75 0.84 (0.67–1.06) 0.89 (0.79–1.00) 0.085 0.64
FD_TH_80 0.90 (0.77–1.04) 0.89 (0.81–0.98) 0.034 0.90 0.85 (0.68–1.05) 0.89 (0.80–1.00) 0.066 0.64
FD_TH_10 1.19 (1.04–1.38) 1.09 (0.99–1.19) 0.022 0.21 1.03 (0.84–1.26) 1.06 (0.96–1.18) 0.479 0.75
Kurtosis 0.86 (0.73–1.00) 0.90 (0.81–0.99) 0.032 0.58 0.98 (0.78–1.22) 0.91 (0.81–1.01) 0.216 0.53
FD_TH_65 0.84 (0.71–0.99) 0.89 (0.80–0.99) 0.035 0.49 0.83 (0.65–1.06) 0.91 (0.81–1.03) 0.170 0.46
FD_Minkowski 0.90 (0.74–1.08) 0.86 (0.77–0.97) 0.042 0.71 0.77 (0.59–1.01) 0.89 (0.78–1.01) 0.063 0.32
Busyness 1.15 (1.00 –1.33) 1.09 (1.00–1.19) 0.053 0.46 0.92 (0.75–1.14) 1.09 (0.99–1.21) 0.128 0.12
Homogeneity 1.05 (0.90–1.22) 1.13 (1.03–1.24) 0.042 0.36 1.06 (0.86–1.31) 1.12 (1.01–1.24) 0.091 0.62
Dissimilarity 0.96 (0.83–1.12) 0.89 (0.81–0.98) 0.057 0.35 0.95 (0.77–1.17) 0.89 (0.81–0.99) 0.110 0.61
FD_TH_60 0.85 (0.71–1.02) 0.9 (0.8–1.01) 0.077 0.56 0.9 (0.69–1.15) 0.92 (0.81–1.04) 0.348 0.85
FD_TH_85 0.92 (0.79–1.06) 0.91 (0.83–1) 0.130 0.98 0.89 (0.72–1.09) 0.91 (0.82–1.01) 0.173 0.77
FD_TH_15 1.2 (1.04–1.39) 1.06 (0.97–1.16) 0.034 0.09 0.96 (0.78–1.18) 1.05 (0.95–1.16) 0.572 0.43
Results are presented as odds ratio (OR) and 95% confidence interval (CI) per 1 standard deviation in normalized feature after adjustment for age, family history,
percent density, and study
*p value refers to two degrees of freedom to test for evidence of association with ductal carcinoma in situ (DCIS) or invasive cancer
**Heterogeneity p value (p het) to test for differences in effect between tumor subgroups
ER estrogen receptor
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increased cancer risk are likely to be a measure of image
heterogeneity or a degree of local tissue disorganization.
Mammograms visualize breast tissue patterns consisting
of epithelial and stromal cells, collagen, and fat. These
tissue components communicate and interact with each
other. Each component may influence the risk and pro-
gression of breast cancer [34]. Entropy associated with an
increased risk of breast cancer and represented a measure
of spatial disorder likely to show a degree of tissue het-
erogeneity. It could be associated with processes on the
cellular level where increased entropy is stated to be as
a metaphor of progressive irreversible loss of initial order
(e.g., by acquiring mutations) in the cell [35]. Another sig-
nificant feature, FD_TH_75, associated with a decreased
risk of breast cancer is also related to tissue heterogeneity
but in the opposite direction. As shown in Fig. 2 (top right
and bottom right images), FD_TH_75 in the bottom 20th
percent tile values represents highly heterogeneous tissue.
Our study had the following limitations. First, many films,
especially from the SFMR, were excluded due to temporal
inconsistencies with the digitization of cases and controls.
Harmonization procedures were needed to rescale the
spatial dimensions and dynamic range. Ideally, all im-
ages would have been digitized on one digitizer, or been
a native digital format (versus film). We also had few
ER– and DCIS cancer subtypes, limiting our power for
these subtypes. For example, the FD_TH_10 and FD_TH_15
features look promising to differentiate DCIS from invasive
cancer because, even with fewer cases, they showed signifi-
cance for DCIS and were not significant for invasive cancers.
However, the heterogeneity p values to test for differences in
effect between DCIS and invasive cancer subgroups
were p = 0.09 and p = 0.21 for FD_TH_15 and FD_TH_10,
respectively. Finally, film mammography has largely been
replaced by full-field digital mammography systems as
well as three-dimensional tomosynthesis systems. How-
ever, texture features measured using film mammograms
have been shown to be in a good agreement with those
measures using digital mammography systems [36]. It is
an important point for future validation of the proposed
texture features to add MLO view mammograms, to esti-
mate rotation-invariant measures by averaging GLCM fea-
tures over the four rotations (0, 45, 90, 135 degrees), and
to apply them for tomosynthesis slices and projections.
Conclusions
We conclude that the description of breast density texture
from mammograms shows promise as an independent risk
factor for breast cancer risk and potentially differentiating
between risks of cancer subtypes. For future work, we plan
to assess risk prediction combining mammographic density
and features assessed on digital mammography and tomo-
synthesis images.
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